Project Start
1994-05-31
Project End
2000-05-31
Budget Start
2000-05-11
Budget End
2000-05-31
Support Year
Fiscal Year
2000
Total Cost
$52,371
Indirect Cost
Name
Saint Louis University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63103
Gorse, Geoffrey J; Simionescu, Ramona E; Patel, Gira B (2006) Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1. Clin Vaccine Immunol 13:26-32
de Bruyn, Guy; Hudgens, Michael G; Sullivan, Patrick S et al. (2005) Participant retention in clinical trials of candidate HIV vaccines. J Acquir Immune Defic Syndr 39:499-501
Lee, Deborah; Graham, Barney S; Chiu, Ya-Lin et al. (2004) Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 190:903-7
Gorse, Geoffrey J; Patel, Gira B; Arbuckle, J Alan et al. (2004) Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection. Vaccine 22:383-97
Gilbert, P B; Chiu, Y-L; Allen, M et al. (2003) Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 21:2933-47
Worku, S; Hoft, D F (2003) Differential effects of control and antigen-specific T cells on intracellular mycobacterial growth. Infect Immun 71:1763-73
Brown, Robin M; Cruz, Orlando; Brennan, Michael et al. (2003) Lipoarabinomannan-reactive human secretory immunoglobulin A responses induced by mucosal bacille Calmette-Guerin vaccination. J Infect Dis 187:513-7
Gupta, Kalpana; Hudgens, Michael; Corey, Lawrence et al. (2002) Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 29:254-61
Evans, T G; McElrath, M J; Matthews, T et al. (2001) QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 19:2080-91
Gorse, G J; Patel, G B; Mandava, M D et al. (2001) Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120. Vaccine 19:1806-19

Showing the most recent 10 out of 22 publications